Binimetinib is a 1-methyl-1H-benzimidazole substituted at positions 4, 5, and 6 with fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1/MEK2 inhibitor (IC50 = 12 nM) and is approved by the FDA for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, in combination with encorafenib. It functions as an MEK inhibitor, an antineoplastic agent, and an apoptosis inducer. It belongs to the classes of benzimidazoles, bromobenzenes, monofluorobenzenes, hydroxamic acid esters, and secondary amino compounds.
